Ryan Cohlhepp Sells 17,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

by · The Cerbat Gem

Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) CEO Ryan Cohlhepp sold 17,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. This trade represents a 8.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

  • On Monday, August 10th, Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00.
  • On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The stock was sold at an average price of $29.00, for a total transaction of $15,544.00.
  • On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72.

Bicara Therapeutics Stock Down 1.3%

BCAX stock opened at $22.81 on Friday. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -7.36 and a beta of -0.82. Bicara Therapeutics Inc. has a 12-month low of $10.30 and a 12-month high of $30.99. The company’s fifty day simple moving average is $25.89 and its 200 day simple moving average is $22.98.

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.82). Research analysts expect that Bicara Therapeutics Inc. will post -3.51 earnings per share for the current year.

Institutional Trading of Bicara Therapeutics

Several large investors have recently made changes to their positions in BCAX. Deutsche Bank AG raised its stake in Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after buying an additional 1,171 shares during the period. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares during the period. Mariner LLC grew its stake in Bicara Therapeutics by 3.0% in the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after acquiring an additional 1,902 shares during the period. Invesco Ltd. increased its holdings in shares of Bicara Therapeutics by 13.2% during the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after acquiring an additional 1,962 shares in the last quarter. Finally, Quantinno Capital Management LP raised its position in shares of Bicara Therapeutics by 16.1% during the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after purchasing an additional 2,447 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. BMO Capital Markets assumed coverage on Bicara Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $35.00 target price for the company. The Goldman Sachs Group boosted their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Citigroup restated a “market outperform” rating on shares of Bicara Therapeutics in a report on Friday, August 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Thursday. Finally, Mizuho lifted their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.64.

Check Out Our Latest Report on BCAX

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

See Also